AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 study.

Rini, Brian; Szczylik, Cezary; M Tannir, Nizar; Koralewski, Piotr; Tomczak, Piotr; Deptala, Andrzej; Y Dirix, Luc; Fishman, Mayer; Ramlau, Rodryg; Ravaud, Alain; Rogowski, Wojciech; Kracht, Karolyn; Sun, Yu-Nien; B Bass, Michael; Puhlmann, Markus; Escudier, Bernard

doi:10.1002/cncr.27632

Public

AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 study.

Shared by NobleBlocks on Dec 15, 2012 • 12:00 AM UTC

Authors:

Brian Rini

Cezary Szczylik

Nizar M Tannir

Abstract

BACKGROUND: This study evaluated the tolerability and antitumor activity of AMG 386, a peptibody (a peptide Fc fusion) that neutralizes the interaction of angiopoietin-1 and angiopoietin-2 with Tie2 (tyrosine kinase with immunoglobulin-like and EGF-like domains 2), plus sorafenib in patients with cl...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!